Description
Allopurinol is indicated to reduce uric acid formation in conditions where uric acid / urate deposits have occurred (gouty arthritis, skin tophi, nephrolithiasis) or in a predictable clinical risk, for example, treatment of certain diseases may produce acute uric acid nephropathy.
Main clinical entities in which uric acid / urate deposits occur:
– Idiopathic gout.
– Uric acid lithiasis.
– Acute uric acid nephropathy.
– Neoplastic disease and myeloproliferative disease with a high degree of cell replacement of which high levels of urates occur, either spontaneously or after cytotoxotic therapy.
– Overproduction of urates caused by certain enzymatic disorders such as: hypoxanthine, guanine, phosphoribosyl-transferase, including Lesch-Nyhan syndrome, glucose-6-phosphatase (glycogen storage disease) -phosphoribosylpyrophosphate synthetase-phosphoribosylpyrophosphate-amidotransferase-phosphoribosylpyrophosphate-transferase-amidotransferase-phosphorous transferase .
Allopurinol is indicated for the management of renal lithiasis due to 2,8-dihydroxyadenine (2,8 DHA), related to the deficient activity of adenine phosphoribosyltransferase.
It is also indicated in the management of recurrent kidney stones mixed with calcium oxalate, in the presence of hyperuricosuria, when dietary measures, control of fluid intake and the like have failed.
Reviews
There are no reviews yet.